Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...

Tubulis today announced the appointment of Charles Fuchs, MD, as Chief Medical Officer (CMO). Dr. Fuchs is an internationally ...

Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...

You may send us your comments on this form by clicking the button below. You will first be asked to supply your name, email address, and location. You must then acknowledge our data protection ...